
Global Pharma Reporter @PharmaScrip, @Norstellaco | Alum: @acjindia | tip/lead: [email protected] | 📩 Signal: Sushmita.33
Delhi, India
Joined August 2011
- Tweets9.5K
- Following963
- Followers4.4K
- Likes21.1K
Pinned Tweet
Super excited to share that I received an Honorary Mention in the #ProjectSirenAwards2025 for my story "FE Mental Health Series | Every 40 seconds, someone dies by suicide – Can we prevent the next?" Grateful for the recognition!
1/3 🔶 Our next honorary mention goes to @SushmitaPanda for her piece in the E Mental Health series, ‘Every 40 seconds, someone dies by suicide—Can we prevent the next?’
Her story frames suicide as a preventable crisis..
Sushmita Panda retweeted
A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced. wapo.st/4t6oIRy
Sushmita Panda retweeted
I don’t know the future of journalism but Jesus Christ, it can’t be this
niemanlab.org/2026/11/after-…
Sushmita Panda retweeted
Rasonque booked $197.6m in roughly five weeks to Sept. 30 after its Aug. 26 FDA approval, the best launch-quarter sales for an oncology drug ever. Revolution’s CEO is still tempering expectations. Why?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
Sushmita Panda retweeted
After taking over epithelial tumors, ADCs are coming for treating sarcomas! Encouraging phase 1 data with the uPARAP-directed ADC ADCE-D01, with 30% ORR across multiple types of sarcoma. Key tox: neutropenia (requiring growth factors), nausea, IRR. #ENA26
Sushmita Panda retweeted
So proud to see my colleague Ritika Chopra in this "TIME 100 India" list. The citation covers the spectacular range of her work — education to politics — and flags all the attributes that make it stand apart: hard work, rigour, nurturing sources, all off camera.
This is an inspiration for all our formidable young talent in the Express newsroom — and beyond.
time.com/collection/time100-…
Sushmita Panda retweeted
In journalism, writer's block often just means you haven't done enough reporting. Conversely, if you can close your eyes & imagine the layout of the piece with some clarity, then it's probably time to start writing
Sushmita Panda retweeted
Story exposing reality of India’s ‘progressive’ abortion law👇🏽
A comment on majority of awful ob-gyn doctors/nurses (mostly women) who don’t seem to have basic training in empathetic, ethical healthcare
In any civilised country they would be stripped of licence and penalised
India’s abortion laws promise women the right to make decisions about their own bodies. But inside hospitals, that choice often comes at the cost of humiliation, coercion, delayed treatment, and medical abuse.
thenewsminute.com/news/the-c…
Sushmita Panda retweeted
Are you thinking of leaving Delhi-NCR because of the air pollution?
Six professionals and founders already did. Here's what they gained, and what it cost them. In today's @IndianExpress 🧵
Sushmita Panda retweeted
the @FDA has declined to approve ivonescimab in advanced NSCLC because of lack of OS benefit*. Interesting how the 'culture' of different diseases affects norms and standards for regulatory approval. The landscape of advanced breast cancer treatment would look very different and have different kinetics if OS was required for approval.
*this instance may also be affected by the fully ex-US nature of the particular trial
smmttx.com/news/press-releas…
Sushmita Panda retweeted
JUST IN: the @FDA has declined to approve PD1/VEGF bispecific ivonescimab in advanced NSCLC with EGFRm, because of lack of OS benefit (via @Reuters) — Having seen approval in several cancers based on PFS, this is somewhat a puzzling rejection.
reuters.com/legal/litigation…
Sushmita Panda retweeted
FDA is shelving the Commissioner's National Priority Voucher program, according to a Reuters report.
Sushmita Panda retweeted
Biopharma CEO "This presentation contains forward-looking statements, as a result of risks and uncertainties..."
AI/Tech CEO "We will cure all diseases in less than 10 years"
$BEAM Therapeutics is targeting a year-end US regulatory filing for risto-cel after the investigational base-editing therapy met the primary efficacy and safety endpoints in its pivotal BEACON trial. My latest for @PharmaScrip
1
106
Sushmita Panda retweeted
Good that you are finally reading a book! Can you please refrain from tweeting about it every 5 mins?
We now have confirmation the PM2.5 hours that went missing in CPCB records on Diwali were the night's worst.
DPCC's updated readings for 30/59 show all above 1,000 µg/m³: Mundka peaked at 3,744, JNU 3,023, Mandir Marg 2,908 and Nehru Nagar 2,808. @htTweets @JasjeevGandhiok
Sushmita Panda retweeted
Breaking:
# Firecrackers accounted for 80% of Delhi's #AirPollution hours after #Diwali night, steadily declining between 1 and 9 am.
Super work by @iitmpune for sharing this real-time source apportionment data.
🙏 @Priyanshi50 for the alert
Sushmita Panda retweeted
Industry’s share of NHS interventional trial enrollment: 3.8% in 2025/26, down from a high of 13.2% in 2017/18. The ABPI calls the trend “worrying” and offers its reading of the cause.
Trial Tuesday. Read it here...
capsul.news/trial-tuesday-uk…





































